Table 4.
Survival of A-strain mice vaccinated with decreasing doses of ACAM3000 in the presences of absence of BCV or vehicle (Anti-Veh).a Mice were vaccinated with 1 × 107, 2 × 106, 4 × 105, or 8 × 104 TCID50 of ACAM3000 at Day 0. At Day 0, 2, 4, and 6 mice also received via oral gavage 20 mg/kg of BCV. At Day 52 (Day 0 rtc), mice were challenged via the IN route with 120 PFU (60× LD50) of ECTV.
| Group | Cage | # of mice | Vaccine treatment (T = 0) |
Antiviral |
ELISA (T = 50, days) | ECTV (T = 52, DAYS) | Time of death (rtc)b | MTD ± SEMb | Mortality (%) at T = 25 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaccine | Dose | Vehicle | BCVa | Vehicle | ||||||||
| 1 | 1 | 15 | − | N/A | + | + | − | 0 | ||||
| 2 | 2 | 11 | − | N/A | + | + | − | + | 8,8,8,8,8,8,8,8,8,8,8 | 8 ± 0 | 100 | |
| 3 |
3 | 15 | + |
1x107 |
− |
+ | + | + |
8,8 | 8 ± 0 | 13⁎ | |
| 4 | 14 | + | + | 10,14, | 12 ± 2 | 14⁎ | ||||||
| 4 |
5 | 15 | + |
2 × 106 |
− |
+ | − | + |
9,9,9,9,10,13,16,20,23 | 13.1 ± 1.8⁎ | 60⁎ | |
| 6 | 15 | + | − | 7,8,8,9,12,14,14,14,14 | 11.1 ± 1⁎ | 60⁎ | ||||||
| 5 |
7 | 15 | + |
4 × 105 |
− |
+ | − | + |
8,8,9,11 | 9 ± 0.7 | 27⁎ | |
| 8 | 14 | + | − | 8,9,13,14,15,16,20 | 13.6 ± 1.6⁎ | 50⁎ | ||||||
| 6 | 9 | 14 | + | 8 × 104 | − | + | − | + | 9,9,9,9,10,10,10,10,14,15,19 | 11.3 ± 1⁎ | 79 | |
| 10 | 12 | + | − | 9,9,9,9,9,10,14,14,15,16 | 11.4 ± 0.9⁎ | 83 | ||||||
ELISA positive animals at T = 50 post vaccination.
⁎
P < 0.05 compared to controls (group 2).
a
Protocol is described in the legend of Fig. 6.
b
BCV, Brincidofovir; rtc, relative to challenge; MTD, mean time to death, SEM, standard error of mean.